Findings

What do systematic reviews say?

10 questions · 10 findings · 7 reviews · Neuromuscular

No studies found 0 · 0%GRADE not reported 4 · 40%Very low 0 · 0%Low 1 · 10%Moderate 5 · 50%High 0 · 0%

Significant adverse events · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
GRADE not reported

Significant adverse events · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
GRADE not reported

Serious adverse events · people with CIDP

Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Adverse events · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

1 finding from 1 review

Significant adverse events · people with inclusion body myositis

Methotrexate probably leads to higher significant adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
RR 8.76 [1.19, 64.28]
1 study · 44 participants
Moderate

Adverse events · 50‐ to 60‐year‐old women with metabolic syndrome

1 finding from 1 review

Non‐drug therapies for the secondary prevention of lower limb muscle cramps 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Moderate

Adverse events · the treatment of diabetic peripheral neuropathy

Acetyl‐L‐carnitine showed no clear difference in adverse events compared with methylcobalamin (low certainty).

1 finding from 1 review

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy 2019 · Cochrane Headline outcomes only
RR 1.01 [0.68, 1.52]
1 study · 232 participants
Low

Serious adverse events · people with CIDP

Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 4.4 [0.22, 86.78]
1 study · 45 participants
Moderate

Adverse events in mitochondrial diseases · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 38 participants
GRADE not reported

Adverse events in glycogen storage disease type V · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 28 participants
GRADE not reported